Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.
about
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentScleroderma lung diseaseSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseasesPulmonary arterial hypertension in France: results from a national registry.Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis.How should we treat vascular and fibrotic lung disease in scleroderma?Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience.Integrated care and optimal management of pulmonary arterial hypertensionIncreased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertensionLung involvement in systemic sclerosis.Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.[Pulmonary hypertension in scleroderma: about 12 cases]Isolated pulmonary hypertension in scleroderma.Pulmonary arterial hypertension in connective tissue diseases.Pulmonary arterial hypertension associated to connective tissue diseases.Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort studyDrug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.Pulmonary arterial hypertension: an overview.Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.Systemic sclerosis-associated myopathy.Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients.Therapies for scleroderma-related pulmonary arterial hypertensionIdiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan.Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease.Care of patients with scleroderma in the intensive care setting.Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward.Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension.Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: a possible pathogenetic role in pulmonary hypertension.Determining the necessity for right heart catheterization in pulmonary hypertension associated with connective tissue diseases assessed by echocardiography.Predictors of end stage lung disease in systemic sclerosis.Improved survival in limited scleroderma-related pulmonary artery hypertension.Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis.Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
P2860
Q33573360-3BEFE626-38DC-495D-B8C2-82C4C9C5157BQ33919119-A765B1DE-A304-4796-8849-E5604ECD91B8Q33965825-0F259071-AFB0-433C-90B3-921C86672F02Q33993302-97A9457A-6ED9-4B16-AD3E-4F367704BC0CQ34013946-3E116034-7385-488F-968C-2E976E693D97Q34167350-C3C18CEE-BBA9-4E2C-9E1E-8FC03820C4E6Q34197167-09B10956-A76B-4826-A680-F35236185F0CQ34417785-8F232FEF-8876-469C-BA6A-AF74BCC3D9FDQ34536425-C51E6506-BDB6-4F7A-BED8-56D56B0F3D5BQ34732817-0309DFAE-F98C-441A-B593-D9410D37DF6AQ34810661-4A3C2F09-34F0-4081-8B42-EE4F89C5BE51Q35552142-212E2858-EAA8-4221-A9EB-B2F7A5C177C7Q35584906-89862311-1568-4827-AA15-E642BE8C3F44Q35637949-D62C47D4-B9E2-4EEE-884F-C9E0A8A9B47EQ35767581-7510E48C-2BD1-482C-900F-ED18353874B9Q36018503-4AD8B16F-316D-4A8E-AE92-0357975A2B68Q36075852-255A5C97-5139-4819-9CF6-A6A12481FFDAQ36283465-D6D44067-2B48-4117-8FED-34CEEE7E2235Q36508730-C8481102-97CE-41A8-8ADA-E35C045EB0F3Q36577383-8352D628-61E2-4440-AA13-DEC7F044E3B2Q36834617-FDAF4AE0-CE5A-4851-92AE-39C319BEE2EEQ36839875-8717CE1F-DDD3-4041-B183-57F59FBAD21DQ36953475-555AA332-3564-41A3-81CA-52EA763AD8BFQ37071471-344DA486-CF1C-4F1F-93D5-9CC1420CF2BEQ37340271-AB16F1CE-1282-48BB-938B-A0CA6E690971Q37364799-D94A9331-6071-4A74-B86B-1788A88EC031Q37609365-29133DDC-EEA5-463C-9D7D-1AEF0E92AD1AQ37672615-2851AB09-F878-4EF7-AC75-1E93581BD5D9Q37764618-998EDB60-6A4F-4507-97BF-B447E4FC41D3Q37880493-16FBD6A8-0A4C-4A0C-9EED-764D50733ECAQ38317794-B3265D7B-DA0D-479C-8387-377092BFB7BDQ39947827-CEB52611-954F-401C-84E8-DF7136580501Q40237047-1E90BA55-DED6-4FA8-84CF-6F5BF80BA737Q40945191-E2DB668C-445A-4AF3-9C56-0FA5A304D96EQ41996144-0F27DE63-C877-4970-9D64-53DE3FBCBEA4Q43517026-4ECBF9D8-C675-4FFE-A6B9-2C5D75DA0C9FQ43838385-50410208-50FA-4B9A-8814-CEC4A79F069CQ45977931-D979C3F2-8820-45D3-A2AC-0855DC9BA29BQ46000874-6B197DE5-4670-4181-B98D-DCC7DBBF6283Q51429838-B49C6A5E-2B9E-4BB7-9BC3-5044F28AEA9B
P2860
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pulmonary hypertension in syst ...... and consequences for survival.
@ast
Pulmonary hypertension in syst ...... and consequences for survival.
@en
Pulmonary hypertension in syst ...... and consequences for survival.
@nl
type
label
Pulmonary hypertension in syst ...... and consequences for survival.
@ast
Pulmonary hypertension in syst ...... and consequences for survival.
@en
Pulmonary hypertension in syst ...... and consequences for survival.
@nl
prefLabel
Pulmonary hypertension in syst ...... and consequences for survival.
@ast
Pulmonary hypertension in syst ...... and consequences for survival.
@en
Pulmonary hypertension in syst ...... and consequences for survival.
@nl
P2093
P356
P1433
P1476
Pulmonary hypertension in syst ...... and consequences for survival.
@en
P2093
MacGregor AJ
P304
P356
10.1093/RHEUMATOLOGY/40.4.453
P577
2001-04-01T00:00:00Z